Extended Data Table 4 Total number of adverse events per treatment group in the safety population

From: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

  1. Data are numbers (%). Listed are grade ≥3 adverse events that were reported in at least 2% of the patients in any treatment group. aIncluding all patients who received at least one dose of study treatment, according to actual study treatment received regardless of randomization.
Back to article page